🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lilly to buy pain drug developer SiteOne, challenging Vertex biopharmadive.com/news/lilly-sit… $LLY $VRTX by Jacob Bell

News Roundup: Biogen strikes RNAi deal with City; Aurion withdraws IPO biopharmadive.com/news/biogen-ci…

GSK-licensed antibiotic meets goal in late-stage study biopharmadive.com/news/gsk-spero… $GSK by Kristin Jensen

FDA leaders seek industry input on ‘listening tour’ biopharmadive.com/news/makary-fd… by Ned Pagliarulo

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says biopharmadive.com/news/veru-enob… $VERU Jon Gardner

Cancer drugmaker iTeos to shut down biopharmadive.com/news/iteos-ope… $ITOS by Gwendolyn Wu

Merck, Daiichi pull approval application for ADC in lung cancer biopharmadive.com/news/merck-dai… $MRK $DSNKY by Ben Fidler

Intellia filing spurs safety concerns over CRISPR drug biopharmadive.com/news/intellia-… $NTLA by Kristin Jensen

HHS terminates Moderna contract to develop bird flu vaccine biopharmadive.com/news/hhs-termi… $MRNA by Delilah Alvarado

J&J data support earlier use of combo pill in prostate cancer biopharmadive.com/news/johnson-j… $JNJ Jon Gardner

Bayer drug could ease side effects of common breast cancer treatment, detailed data show biopharmadive.com/news/bayer-asc… $BAYRY by Delilah Alvarado

Bispecific competition, debating oral SERDs and a bold GLP-1 prediction biopharmadive.com/news/asco-2025… #ASCO2025

Lilly partners with Camurus in search of a long-lasting obesity drug biopharmadive.com/news/eli-lilly… $LLY $CAMRF by Kristin Jensen

News Roundup: Regeneron makes obesity push; Atai, Alto ink brain drug deals biopharmadive.com/news/regeneron…

#Biotech funding plummets as Trump policies unnerve investors: Jefferies biopharmadive.com/news/biotech-f… by Jacob Bell

Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from #ASCO25 biopharmadive.com/news/asco-2025…

FDA to use new review tool on Sarepta’s gene therapy work biopharmadive.com/news/sarepta-p… $SRPT by Ben Fidler

Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal biopharmadive.com/news/cullinan-… $CGEM by Kristin Jensen

News Roundup: Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update biopharmadive.com/news/otsuka-ve…

FDA meeting gives window into gene therapy field’s angst biopharmadive.com/news/fda-gene-… by Ned Pagliarulo